Eli Lilly and Company $LLY is Blodgett Wealth Advisors LLC’s 9th Largest Position

Blodgett Wealth Advisors LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 10.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,759 shares of the company’s stock after selling 438 shares during the quarter. Eli Lilly and Company comprises 2.7% of Blodgett Wealth Advisors LLC’s investment portfolio, making the stock its 9th biggest holding. Blodgett Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $3,457,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Carmel Capital Partners LLC raised its holdings in Eli Lilly and Company by 1.7% in the first quarter. Carmel Capital Partners LLC now owns 657 shares of the company’s stock worth $604,000 after purchasing an additional 11 shares in the last quarter. Costello Asset Management INC boosted its holdings in shares of Eli Lilly and Company by 15.8% during the 1st quarter. Costello Asset Management INC now owns 10,010 shares of the company’s stock valued at $9,207,000 after buying an additional 1,367 shares in the last quarter. Whipplewood Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 213.8% during the 1st quarter. Whipplewood Advisors LLC now owns 91 shares of the company’s stock valued at $84,000 after buying an additional 62 shares in the last quarter. Accredited Investors Inc. grew its position in shares of Eli Lilly and Company by 6.6% in the 1st quarter. Accredited Investors Inc. now owns 4,250 shares of the company’s stock worth $3,909,000 after buying an additional 264 shares during the period. Finally, Graetz Wealth LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $231,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,189.06 on Friday. The firm has a market cap of $1.12 trillion, a P/E ratio of 42.24, a PEG ratio of 1.51 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a 50 day moving average of $1,098.66 and a 200 day moving average of $1,033.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue was up 55.5% compared to the same quarter last year. During the same period last year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 35.81 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a research report on Monday. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Morgan Stanley raised their target price on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research note on Wednesday. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Finally, Rothschild & Co Redburn boosted their price target on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,263.41.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bank of America raised its price target on Eli Lilly to $1,334 from $1,251 and kept a buy rating, signaling confidence that the company still has meaningful upside after its recent run. Benzinga article
• Positive Sentiment: Lilly announced that its Phase 2 neuropathic pain trial reached completion, adding another potentially valuable pipeline asset beyond its blockbuster GLP-1 franchise. TipRanks article
• Positive Sentiment: News flow highlighting record GLP-1 adoption and accelerating sales remains supportive, since Lilly’s obesity and diabetes drugs continue to be the main driver of earnings momentum. Motley Fool article
• Positive Sentiment: Additional analyst commentary has been upbeat, with other firms also lifting targets and framing Lilly as one of the strongest growth names in healthcare. TheStreet article
• Neutral Sentiment: Institutional buying and “best mutual funds” lists suggest Lilly remains a favored large-cap healthcare holding, but this is more a sentiment indicator than a direct catalyst. Yahoo Finance article
• Negative Sentiment: Tampa General’s lawsuit over allegedly pulled 340B discounts adds legal and reimbursement risk, which could create some investor caution around Lilly’s pricing and hospital-channel relationships. Healthcare Finance News article

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.